Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.53 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | PYGL | P06737 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955043 | 0.89 | HSPB1 (0.50) | HPSEHSPB1PYGLMAPTPAX8 | |
| SCHEMBL10594864 | 0.87 | KDM4E (0.62) | KDM4EHPSEMRGPRX4AKR1C3MAPT | |
| SCHEMBL1341586 | 0.86 | ALDH1A1 (0.57) | HSPB1MRGPRX4PYGLMAPTPAX8 | |
| SCHEMBL28256432 | 0.86 | KDM4E (0.69) | KDM4EHPSEHSPB1MRGPRX4AKR1C3 | |
| SCHEMBL2962096 | 0.85 | L3MBTL1 (0.48) | HPSEHSPB1MAPTPAX8SMN1; SMN2 | |
| SCHEMBL2966318 | 0.85 | MRGPRX4 (0.67) | KDM4EHPSEMRGPRX4AKR1C3MAPT | |
| SCHEMBL10662277 | 0.84 | LMNA (0.61) | KDM4EHPSEMRGPRX4AKR1C3PYGL | |
| SCHEMBL2970880 | 0.83 | SMN1; SMN2 (0.49) | KDM4EHSPB1MAPTPAX8SMN1; SMN2 | |
| SCHEMBL1638040 | 0.83 | HSPB1 (0.66) | HPSEHSPB1MAPTCRHBPCRHR2 | |
| SCHEMBL31090823 | 0.83 | HSPB1 (0.66) | HPSEHSPB1MAPTCRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338605-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100256139-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-1979349-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2010-07-28 | — | — | EP | disclosed |
| US-7763731-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2010-07-27 | — | — | US | disclosed |
| US-7572783-B2 | Obesity; N-(1-benzyl-piperidin-4-yl)-2-(2,5-dioxo-7-phenoxy-1,2,3,5-tetrahydro-benzo[e][1,4]diazepin-4-yl)-3-methyl-butyramide; modulators of ghrelin receptor (GHSR) | AMGEN INC. (US) | 2009-08-11 | — | — | US | disclosed |
| EP-1979349-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| WO-2007076035-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
| EP-1784390-A2 | SUBSTITUTED BENZOFUSED HETEROCYCLES | Amgen Inc. (US) | 2007-05-16 | — | — | EP | disclosed |
| US-20060199796-A1 | Substituted benzofused heterocycles | AMGEN INC. (US) | 2006-09-07 | — | — | US | disclosed |
| WO-2006020959-A2 | SUBSTITUTED BENZOFUSED HETEROCYCLES | AMGEN INC. (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232645-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | KDM4E 1822/4885HPSE 65/4885HSPB1 2200/4885 |
| US-20060199796-A1 | Substituted benzofused heterocycles | GPR119, SDHA, OGDH | KDM4E 343/4885HPSE 1783/4885HSPB1 3323/4885 |
| US-20100256139-A1 | Anti-Viral Compounds | HAVCR2, MAVS, EIF2AK2 | KDM4E 1822/4885HPSE 65/4885HSPB1 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.